trending Market Intelligence /marketintelligence/en/news-insights/trending/03xd6cfb7kyoxtdbupimeq2 content esgSubNav
In This List

Esperion appoints director

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Esperion appoints director

Esperion Therapeutics Inc. appointed Jay Shepard as a class III director, with a term expiring at the company's 2019 annual meeting of stockholders.

Shepard has served as the president and CEO of Versartis Inc. since May 2015.

Ann Arbor, Mich.-based Esperion Therapeutics is a lipid management company, which focuses on developing and commercializing oral therapies to treat elevated low-density lipoprotein cholesterol.